NewsRoom Articles - Page 41 of 235

TuesdayFeb 25, 2025 10:00 am

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

The worldwide e-commerce market is predicted to expand by 7.8% and reach a market value of $6.5 trillion by the end of this year. As an e-commerce operator, it is in your best interest to leverage the emerging trends so that your business can claim its fair share of this expanding market. We discuss some of those trends below. Social Commerce This is one big trend to watch if you are into e-commerce. Social media as well as other digital channels are the hallmarks in this trend. The concept allows transactions to happen easily between businesses and their target clientele.…

MondayFeb 24, 2025 1:00 pm

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

According to the American Cancer Society, cancer is the second leading cause of death globally. Oncology drugs are a cornerstone of modern cancer treatment. Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.…

FridayFeb 21, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…

FridayFeb 21, 2025 10:00 am

Europe is Facing a Growing Shortfall of General Practitioners

Data shows that Europe is facing a growing deficit of doctors across all specialties, and the declining number of general practitioners stands out strongly. Current GPs aren’t evenly distributed and the fact that they are aging and leaving active service makes the problem worse. Traditionally, GPs have served as the first point of contact when someone is facing a health challenge. These professionals handle most patients and refer those who need additional care to specialists. This primary healthcare role has earned them the tag ‘family doctor.’ However, countries across Europe are faced with a double whammy; their general populations are…

FridayFeb 21, 2025 10:00 am

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Shifting to value-based care improves patient outcomes and cost-effective provider efficiency. Adageis’ ProActive Care shifts focus from reactive treatment to preventive, patient-centered care, with AI-driven analytics identifying high-risk patients and addressing care gaps. Patients receive more personalized, effective treatment, rather than a volume treatment driven approach. Better patient outcomes lead to reduced hospitalizations and cost savings, while increased cost monitoring and efficiency for providers supports increased revenue and net income potential. For many patients, the American healthcare system often feels rushed, transactional and fragmented. Doctors have limited time, and treatment decisions can be driven by billing structures rather than patient…

ThursdayFeb 20, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns

Rising cancer numbers indicate urgent need for advancements in cancer research, and stem cell research is rising to meet the challenge. Stem cells are being explored not only as a tool to regenerate damaged tissues but also as a delivery vehicle for innovative cancer treatments. Calidi Biotherapeutics stands at the forefront of integrating stem cell technology into oncology. As 2025 approaches, cancer continues to be one of the most significant global health challenges. Projections indicate a sharp increase in cancer diagnoses, with new cases in 2024 expected to surpass 2 million annually in the United States for the first time.…

ThursdayFeb 20, 2025 10:00 am

Scientists Discover ‘Roadmap’ Followed by Aggressive Cancers to Spread

A new study whose findings were published in the Nature Communications journal has shown how tumor cells are changed by the environment around them. Because of these alterations, cancer cells alter their shape, thereby escaping from the tumor and spreading to other parts of the organ or body. The findings of this study have been almost 10 years in the making and they open the door for the development of interventions that could treat cancer prior to its spread. To understand why this study is pivotal, one must understand the structure of a tumor. Tumors are contained within a structure…

FridayFeb 14, 2025 10:00 am

Analysis Uncovers Key Insights About Insurers’ Medical Advantage Prior Authorization Decisions

Nearly all people who enroll for Medical Advantage plans are expected to secure prior authorization when they need certain services, such as skilled nursing facility care, in-patient stays at hospitals and services that cost a lot, such as chemotherapy. A recent analysis revealed critical insights about MA prior authorizations in 2023. We share some of them in the discussion below. 50 million applications were made for prior authorizations The data submitted to CMS shows that insurance firms providing MA coverage made 50 million determinations with regard to prior authorization requests. This number conforms to a pattern of steady growth that…

ThursdayFeb 13, 2025 10:00 am

Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes

An ongoing clinical trial aims to test a drug that is hoped to avert Alzheimer’s disease decades before it is expected to manifest in an individual. This study is being conducted by a team at the School of Medicine at Washington University. The drug in question, remternetug, was formulated by Eli Lilly and is intended to clear plaque from the brains of young people that have been found to have a genetic predisposition to developing Alzheimer’s disease. The study subjects are young people, some of them 18 years old, expected to develop the disease early (from their 30s onwards). In…

TuesdayFeb 11, 2025 1:35 pm

How Adageis Uses Data to Drive Value-Based Care Adoption and Boost Revenue for Healthcare Providers

Value-based care models prioritize proactive, high-quality patient care, and, if done correctly, can significantly enhance financial outcomes. Healthcare organizations adopting a value-based care approach can see increased revenue through efficiency, reduced hospitalizations and incentive payments. Adageis provides AI-driven solutions that help providers transition to and optimize value-based care models. The company’s data analytics features play a critical role in identifying high-risk patients, closing care gaps and controlling costs. Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

Europe is Facing a Growing Shortfall of General Practitioners

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns

Scientists Discover ‘Roadmap’ Followed by Aggressive Cancers to Spread

Analysis Uncovers Key Insights About Insurers’ Medical Advantage Prior Authorization Decisions

Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes

How Adageis Uses Data to Drive Value-Based Care Adoption and Boost Revenue for Healthcare Providers

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search